S227 – BRECADD: THE OPTIMAL TREATMENT FOR ADVANCED-STAGE HODGKIN LYMPHOMA — A METANALYSIS AND AN INDIRECT COMPARISON WITH INDIVIDUAL PATIENT DATA EXTRACTION
This program has been made possible through unrestricted support from Eli Lilly, Merck & Roche.
Studies/trials discussed:
S227 – BRECADD: THE OPTIMAL TREATMENT FOR ADVANCED-STAGE HODGKIN LYMPHOMA — A METANALYSIS AND AN INDIRECT COMPARISON WITH INDIVIDUAL PATIENT DATA EXTRACTION